Literature DB >> 25223268

Influenza vaccine effectiveness estimates for Western Australia during a period of vaccine and virus strain stability, 2010 to 2012.

Avram Levy1, Sheena G Sullivan2, Simone S Tempone1, Kerry L M Wong3, Annette K Regan4, Gary K Dowse4, Paul V Effler4, David W Smith1.   

Abstract

During 2010-2012 the strain composition of the influenza vaccine in the Southern Hemisphere did not change, but the circulating virus type/subtype did. We pooled data for these years from the Western Australian sentinel medical practice surveillance system for influenza to estimate vaccine effectiveness (VE) by influenza virus type and subtype. A case test-negative design was used with VE estimated as (1-odds ratio)×100%. There were 2182 patients included in the analysis across the 3 years studied. The predominant subtype was A/H1pdm09 in 2010 and 2011, and A/H3 in 2012. The overall adjusted VE estimate against all influenza for 2010-2012 was 51% (95% CI: 36, 63). Estimates were highest against A/H1pdm09 at 74% (95% CI: 47, 87), followed by 56% (95% CI: 33, 71) for influenza B and lowest against A/H3 at 39% (95% CI: 13, 57). When analyses were restricted to compare influenza-positive patients with patients who tested positive for a non-influenza virus, overall adjusted VE was 59% (95% CI: 39, 72). These results suggest moderate protection against influenza by vaccination in Western Australia over the period 2010-2012, and are consistent with findings from other settings.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Data pooling; Influenza; Influenza season; Influenza vaccine; Influenza-like illness; Vaccine effectiveness

Mesh:

Substances:

Year:  2014        PMID: 25223268     DOI: 10.1016/j.vaccine.2014.08.066

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Influenza vaccine effectiveness by test-negative design - Comparison of inpatient and outpatient settings.

Authors:  Shuo Feng; Benjamin J Cowling; Sheena G Sullivan
Journal:  Vaccine       Date:  2016-02-23       Impact factor: 3.641

2.  Data-driven interdisciplinary mathematical modelling quantitatively unveils competition dynamics of co-circulating influenza strains.

Authors:  Bin-Shenq Ho; Kun-Mao Chao
Journal:  J Transl Med       Date:  2017-07-28       Impact factor: 5.531

3.  Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness.

Authors:  Sheena G Sullivan; Eric J Tchetgen Tchetgen; Benjamin J Cowling
Journal:  Am J Epidemiol       Date:  2016-09-01       Impact factor: 4.897

4.  Assessment of Virus Interference in a Test-negative Study of Influenza Vaccine Effectiveness.

Authors:  Shuo Feng; Ashley L Fowlkes; Andrea Steffens; Lyn Finelli; Benjamin J Cowling
Journal:  Epidemiology       Date:  2017-07       Impact factor: 4.822

5.  The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.

Authors:  Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

6.  Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010-13, United States.

Authors:  Benjamin J Cowling; Shuo Feng; Lyn Finelli; Andrea Steffens; Ashley Fowlkes
Journal:  Vaccine       Date:  2015-11-21       Impact factor: 3.641

7.  Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States.

Authors:  Manjusha Gaglani; Jessica Pruszynski; Kempapura Murthy; Lydia Clipper; Anne Robertson; Michael Reis; Jessie R Chung; Pedro A Piedra; Vasanthi Avadhanula; Mary Patricia Nowalk; Richard K Zimmerman; Michael L Jackson; Lisa A Jackson; Joshua G Petrie; Suzanne E Ohmit; Arnold S Monto; Huong Q McLean; Edward A Belongia; Alicia M Fry; Brendan Flannery
Journal:  J Infect Dis       Date:  2016-01-06       Impact factor: 7.759

8.  Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer.

Authors:  Rishi S Kotecha; Ushma D Wadia; Peter Jacoby; Anne L Ryan; Christopher C Blyth; Anthony D Keil; Nicholas G Gottardo; Catherine H Cole; Ian G Barr; Peter C Richmond
Journal:  Cancer Med       Date:  2015-12-29       Impact factor: 4.452

9.  Pooled influenza vaccine effectiveness estimates for Australia, 2012-2014.

Authors:  S G Sullivan; K S Carville; M Chilver; J E Fielding; K A Grant; H Kelly; A Levy; N P Stocks; S S Tempone; A K Regan
Journal:  Epidemiol Infect       Date:  2016-04-29       Impact factor: 4.434

10.  Assessment of potential public health impact of a quadrivalent inactivated influenza vaccine in Thailand.

Authors:  Wanitchaya Kittikraisak; Malinee Chittaganpitch; Christopher J Gregory; Yongjua Laosiritaworn; Thanawadee Thantithaveewat; Fatimah S Dawood; Kim A Lindblade
Journal:  Influenza Other Respir Viruses       Date:  2016-01-29       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.